Understand the source comparison
Tesamorelin FAQ: Dosing, Mechanism, and Research Use Comparison
The table below compares tesamorelin to other growth hormone secretagogues based on mechanism, half-life, dosing frequency, and primary research applications. Understanding these distinctions clarifies why tesamorelin produces different outcomes than compounds
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below compares tesamorelin to other growth hormone secretagogues based on mechanism, half-life, dosing frequency, and primary research applications. Understanding these distinctions clarifies why tesamorelin produces different outcomes than compounds often mentioned alongside it.
- Tesamorelin
- GHRH receptor agonist
- 26–38 minutes
- 2 mg SC daily (evening)
- Visceral adipose tissue reduction in lipodystrophy
- Targets visceral fat specifically via pulsatile GH release; FDA-approved for HIV lipodystrophy; minimal appetite effects
- Sermorelin
- ~10 minutes
- 200–500 mcg SC daily
- Anti-aging and body composition research
- Shorter half-life than tesamorelin; similar mechanism but less stable; often used in longevity protocols
- Ipamorelin
- Ghrelin receptor agonist
- ~2 hours
- 200–300 mcg SC 2–3× daily
- GH release without cortisol/prolactin elevation
- Synergistic with GHRH agonists; minimal side effects; does not elevate cortisol like GHRP-6
- CJC-1295 (with DAC)
- 6–8 days
- 2 mg SC weekly
- Sustained GH elevation research
- Long half-life allows weekly dosing; higher risk of desensitization; less physiological pulsatility
- MK-677 (Ibutamoren)
- Ghrelin receptor agonist (oral)
- 4–6 hours
- 10–25 mg oral daily
- Oral GH secretagogue research
- Oral bioavailability; increases appetite significantly; elevates cortisol and prolactin more than ipamorelin
- Tesamorelin's specificity for visceral adipose tissue makes it the preferred choice when central obesity is the primary concern. Combining it with ipamorelin, as in the Tesamorelin Ipamorelin Growth Hormone Stack, leverages dual receptor pathways without redundancy. MK 677, by contrast, offers oral convenience but comes with appetite stimulation that can counteract fat loss efforts. A trade-off worth considering based on research objectives.